Results 51 to 60 of about 3,163,010 (367)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Blood, 2017
Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked
E. Stein, C. Dinardo, D. Pollyea, A. Fathi, G. Roboz, J. Altman, R. Stone, D. DeAngelo, R. Levine, I. Flinn, H. Kantarjian, R. Collins, M. Patel, A. Frankel, A. Stein, M. Sekeres, R. Swords, B. Medeiros, C. Willekens, P. Vyas, A. Tosolini, Qiang Xu, R. Knight, K. Yen, S. Agresta, S. de Botton, M. Tallman   +26 more
semanticscholar   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach [PDF]

Converg. Sci. Phys. Oncol. 1 (2015) 025002, 2014
Complex phenotypic differences among different acute leukemias cannot be fully captured by analyzing the expression levels of one single molecule, such as a miR, at a time, but requires systematic analysis of large sets of miRs. While a popular approach for analysis of such datasets is principal component analysis (PCA), this method is not designed to ...
arxiv   +1 more source

Acute Megakaryocytic Leukemia [PDF]

Cold Spring Harbor Perspectives in Medicine, 2019
Acute megakaryoblastic leukemia (AMKL) is a rare malignancy affecting megakaryocytes, platelet-producing cells that reside in the bone marrow. Children with Down syndrome (DS) are particularly prone to developing the disease and have a different age of onset, distinct genetic mutations, and better prognosis as compared with individuals without DS who ...
Maureen McNulty, John D. Crispino
openaire   +3 more sources

Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

New England Journal of Medicine, 2018
Background In a single‐center phase 1–2a study, the anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and ...
S. Maude, T. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. Verneris, H. Stefanski, G. D. Myers, M. Qayed, B. De Moerloose, H. Hiramatsu, Krysta D Schlis, K. Davis, P. Martin, Eneida R. Nemecek, G. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. June, B. Levine, P. Wood, T. Taran, M. Leung, K. Mueller, Yiyun Zhang, K. Sen, D. Lebwohl, M. Pulsipher, S. Grupp   +34 more
semanticscholar   +1 more source

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

Molecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale, Li Li, J. Kyle Bruner, Melody Chou, Bao Nguyen, Jaesung Seo, Ruiqi Zhu, Mark J. Levis, Christine A. Pratilas, Donald Small   +9 more
wiley   +1 more source

IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia

Translational Oncology, 2022
Cytokine Receptor-Like Factor 2 (CRLF2) overexpression occurs in 5-15% of B-cell precursor acute lymphoblastic leukaemia (B-ALL). In ∼50% of these cases, the mechanisms underlying this dysregulation are unknown.
Ana Luiza Tardem Maciel, Thayana da Conceição Barbosa, Caroline Barbieri Blunck, Karolyne Wolch, Amanda de Albuquerque Lopes Machado, Elaine Sobral da Costa, Lavínia Lustosa Bergier, Márcia Trindade Schramm, Maura Rosane Valério Ikoma-Coltutato, Mecneide Mendes Lins, Thais Ferraz Aguiar, Marcela Braga Mansur, Mariana Emerenciano   +12 more
doaj  

Hierarchy in Gene Expression is Predictive for Adult Acute Myeloid Leukemia [PDF]

, 2015
Cancer progresses with a change in the structure of the gene network in normal cells. We define a measure of organizational hierarchy in gene networks of affected cells in adult acute myeloid leukemia (AML) patients. With a retrospective cohort analysis based on the gene expression profiles of 116 acute myeloid leukemia patients, we find that the ...
arxiv   +1 more source

Functional Genomic Landscape of Acute Myeloid Leukemia

Nature, 2018
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events.
J. Tyner, C. Tognon, D. Bottomly, Beth Wilmot, S. Kurtz, S. Savage, Nicola Long, Anna Reister Schultz, E. Traer, Melissa L. Abel, A. Agarwal, A. Blucher, U. Borate, Jade Bryant, Russell T. Burke, A. Carlos, Richie Carpenter, J. Carroll, B. Chang, Cody Coblentz, Amanda d’Almeida, R. Cook, A. Danilov, K. Dao, Michie Degnin, D. Devine, J. Dibb, David K Edwards, C. Eide, I. English, J. Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, A. Kaempf, Jessica T. Leonard, Chen-Jzong Lin, S. Liu, Pierrette Lo, M. Loriaux, Samuel B. Luty, T. Macey, Jason D. MacManiman, Jacqueline Martinez, M. Mori, D. Nelson, Ceilidh Nichols, Jill Peters, Justin W Ramsdill, Angela Rofelty, R. Schuff, R. Searles, E. Segerdell, Rebecca Smith, S. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jacob P. Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, C. Cogle, R. Collins, D. Connolly, M. Deininger, L. Drusbosky, C. Hourigan, C. Jordan, P. Kropf, Tara L. Lin, Micaela E. Martinez, B. Medeiros, Rachel R. Pallapati, D. Pollyea, R. Swords, J. Watts, S. Weir, D. Wiest, R. M. Winters, S. McWeeney, B. Druker   +87 more
semanticscholar   +1 more source

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

Molecular Oncology, EarlyView.
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa, Zdenka Herudkova, Jan Hyl, Jakub Vlazny, Filip Sokol, Kvetoslava Matulova, Adam Folta, Jakub Hynst, Lucy Vojtova, Leos Kren, Martin Repko, Zdenek Racil, Jiri Mayer, Martin Culen   +13 more
wiley   +1 more source